

# Quality for Biologics

## Part Three: Impurity Profiles and Product Variation

*Product- and process-related impurities, aggregation and non-clinical testing*

### Table of Contents

#### Chapter 9

#### **Impurity Profile: How the Process can Impact on the Impurity Profile, and Characterisation of Product and Process Related Impurities**

**Stefan Zietze MSc PhD, *Head of Quality Control*,  
Marco Riedel PhD, *Director of Q A, Qualified Person*,  
ProBioGen, Berlin, Germany**

1. Nature of product- and process-related impurities
2. Characterization of product- and process-related impurities
3. Impact of impurities on product quality

#### Chapter 10

#### **Impact of the Process on Aggregation, and Technologies for Aggregation Analysis**

**Professor Nigel Jenkins, *Principal Investigator*, National Institute of Bioprocessing Research and Training (NIBRT), University College Dublin, Ireland  
Dr Ray Tyther, *Senior Scientist*, NIBRT Laboratory, National Institute for Cellular Biotechnology (NICB), Dublin City University, Ireland  
Dr Lisa Murphy, *Senior Scientist*, NIBRT Laboratory, National Institute for Cellular Biotechnology (NICB), Dublin City University, Ireland**

1. Introduction
2. Interventions in the protein secretory pathway
3. Disulphide bond formation
4. Chaperones
5. Multiple gene activators
6. Environmental conditions
7. Analytical methods to detect misfolding and aggregation
8. Conclusions

#### Chapter 11

#### **Importance of Non-Clinical Testing**

**Nadja Prang-Richard PhD MBA, *Program Director for Monoclonal Antibodies*, LFB, France and *Co-Founder & Scientific Advisory Board Member*, Lophius, Biosciences, Germany**

1. Introduction
2. Regulatory aspects
3. In vitro systems
4. In vivo systems
5. Pharmacokinetics

6. Toxicology studies
7. Non-clinical testing in (BIO)pharmaceutical development

## **About the Contributors**